
Clinical Trials - December 2, 2014
Ascendis Fundraising for Trial
Danish biotech Ascendis Pharma has put together a $60 million D round, cash that will help get its once-a-week treatment for growth hormone deficiency (GHD) into late-stage testing. Ascendis is relying on a technology called TransCon, a hydrogel made of prodrug linkers that seek out targeted molecules in the body and then release their dosage.The […]